Martina Menchini1, Francesco Sartini2, Michele Figus2, Giovanna Gabbriellini2. 1. Ophthalmology, Department of Surgical, Medical, Molecular Pathology and Critical Care Medicine, University of Pisa, Via Savi, 10, 56126, Pisa, Italy. martina.mmenchini@gmail.com. 2. Ophthalmology, Department of Surgical, Medical, Molecular Pathology and Critical Care Medicine, University of Pisa, Via Savi, 10, 56126, Pisa, Italy.
Abstract
BACKGROUND: We investigated the safety and efficacy of short-term treatment with topical low-dose hydrocortisone sodium phosphate 0.335% (PFH) in patients with moderate to severe primary Sjögren syndrome (SS)-related dry eye disease (DED). METHODS: A retrospective single-centre interventional study. All patients received PFH for 6 days with a pulsed posology: three times daily for 2 days, twice daily for 2 days, and once daily for 2 days. This scheme was repeated for 3 consecutive months and then alternated for 3 months. Data were collected at baseline, 3 months, and 6 months of follow-up. RESULTS: A total of 40 SS patients were enrolled. Conjunctival hyperaemia and corneal-conjunctival stain significantly improved (p < 0.001). Ocular Surface Disease Index score reduced significantly between baseline and 3 months and between baseline and 6 months (p < 0.001). The tear film osmolarity lowered significantly in each eye from baseline to 3 months and from baseline to 6 months (p = 0.002 and p = 0.037, respectively). Comparing results at 3 and 6 months, the Ocular Surface Disease Index score (p = 1.000), the frequency of lacrimal substitutes installation (p = 0.632), and tear film osmolarity (right eye p = 0.518, left eye p = 1.000) did not change significantly. Intraocular pressure did not change during the study period. CONCLUSION: PFH eye drops with a pulsed posology improve signs and symptoms, not affecting the intraocular pressure in SS-related DED. Therefore, this pulsed treatment is safe and efficacious.
BACKGROUND: We investigated the safety and efficacy of short-term treatment with topical low-dose hydrocortisone sodium phosphate 0.335% (PFH) in patients with moderate to severe primary Sjögren syndrome (SS)-related dry eye disease (DED). METHODS: A retrospective single-centre interventional study. All patients received PFH for 6 days with a pulsed posology: three times daily for 2 days, twice daily for 2 days, and once daily for 2 days. This scheme was repeated for 3 consecutive months and then alternated for 3 months. Data were collected at baseline, 3 months, and 6 months of follow-up. RESULTS: A total of 40 SS patients were enrolled. Conjunctival hyperaemia and corneal-conjunctival stain significantly improved (p < 0.001). Ocular Surface Disease Index score reduced significantly between baseline and 3 months and between baseline and 6 months (p < 0.001). The tear film osmolarity lowered significantly in each eye from baseline to 3 months and from baseline to 6 months (p = 0.002 and p = 0.037, respectively). Comparing results at 3 and 6 months, the Ocular Surface Disease Index score (p = 1.000), the frequency of lacrimal substitutes installation (p = 0.632), and tear film osmolarity (right eye p = 0.518, left eye p = 1.000) did not change significantly. Intraocular pressure did not change during the study period. CONCLUSION: PFH eye drops with a pulsed posology improve signs and symptoms, not affecting the intraocular pressure in SS-related DED. Therefore, this pulsed treatment is safe and efficacious.
Authors: Lyndon Jones; Laura E Downie; Donald Korb; Jose M Benitez-Del-Castillo; Reza Dana; Sophie X Deng; Pham N Dong; Gerd Geerling; Richard Yudi Hida; Yang Liu; Kyoung Yul Seo; Joseph Tauber; Tais H Wakamatsu; Jianjiang Xu; James S Wolffsohn; Jennifer P Craig Journal: Ocul Surf Date: 2017-07-20 Impact factor: 5.033
Authors: Jennifer P Craig; Kelly K Nichols; Esen K Akpek; Barbara Caffery; Harminder S Dua; Choun-Ki Joo; Zuguo Liu; J Daniel Nelson; Jason J Nichols; Kazuo Tsubota; Fiona Stapleton Journal: Ocul Surf Date: 2017-07-20 Impact factor: 5.033
Authors: Gary N Foulks; S Lance Forstot; Peter C Donshik; Joseph Z Forstot; Michael H Goldstein; Michael A Lemp; J Daniel Nelson; Kelly K Nichols; Stephen C Pflugfelder; Jason M Tanzer; Penny Asbell; Katherine Hammitt; Deborah S Jacobs Journal: Ocul Surf Date: 2015-01-15 Impact factor: 5.033
Authors: Roland Jonsson; Petra Vogelsang; Roman Volchenkov; Alexander Espinosa; Marie Wahren-Herlenius; Silke Appel Journal: Immunol Lett Date: 2011-07-12 Impact factor: 3.685
Authors: Feisal A Adatia; Adi Michaeli-Cohen; Joel Naor; Barbara Caffery; Arthur Bookman; Allan Slomovic Journal: Can J Ophthalmol Date: 2004-12 Impact factor: 1.882
Authors: Martin Kallab; Stephan Szegedi; Nikolaus Hommer; Hannes Stegmann; Semira Kaya; René M Werkmeister; Doreen Schmidl; Leopold Schmetterer; Gerhard Garhöfer Journal: Adv Ther Date: 2019-11-18 Impact factor: 3.845
Authors: Barbara Segal; Simon J Bowman; Philip C Fox; Frederick B Vivino; Nandita Murukutla; Jeff Brodscholl; Sarika Ogale; Lachy McLean Journal: Health Qual Life Outcomes Date: 2009-05-27 Impact factor: 3.186